Volume 49, June 2014 loss of carnitine, hemodialysis, patients taking medications including valproic acid and zidovudine, patients on prolonged PN, and neonates and infants. 3 Carnitine has been considered a conditional essential nutrient in pediatrics. 4, 5 It is initially transferred to the fetus during the third trimester of a pregnancy. Once the child is born, carnitine is typically obtained from the mother's breast milk or infant formula. However, if the child is not able to take food by mouth and receives total PN without carnitine supplementation, he or she is likely to deplete their carnitine stores.
Neonates and infants are generally unable to synthesize enough carnitine on their own due to their immature liver and kidneys. To biosynthesize carnitine, there must be adequate supplies of cofactors including ascorbic acid, iron, niacin, and pyridoxine. 3 The fi nal step of carnitine biosynthesis requires γ-butyrobetaine hydroxylase. The pediatric population has about only 12% of this enzyme compared to adults. 3 As a result, some infants are not able to synthesize enough carnitine.
Carnitine is stored in the skeletal muscle, heart, liver, brain, and kidney and within plasma. 4 Carnitine is also found in the body in several different forms. Because of this, it can be diffi cult to assess a carnitine defi ciency. Studies have defi ned carnitine defi ciency as a free plasma carnitine concentration of less than 20 nmol/mL. An insuffi ciency is defi ned as an acylcarnitine to free carnitine ratio of greater than 0.4. 1 A carnitine defi ciency or insuffi ciency is based on the combination of decreased carnitine laboratory values and clinical symptoms. Depending on the severity of the defi ciency, the infant may present with myopathies, limb weakness, hypotonia, hypoglycemia, hyperbilirubinemia, hypoketonemia, encephalopathy, coma, or even death. 2, 3, 4, 6 Studies have assessed the benefi ts of carnitine supplementation in infants and neonates. Most of these studies have looked at the very-low-birth-weight infants on PN and/or enteral feeds. The results have been inconsistent on carnitine supplementation in regard to weight gain and morbidity markers including episodes of apnea. None of these studies have had large sample sizes or been consistent in the method of carnitine supplementation. Additionally, none have evaluated different patient weight ranges in which supplementation should be empirically started versus when a carnitine level should be drawn. Two systematic reviews have been published and both concluded that there is not enough evidence to support routine supplementation of parenterally fed neonates despite the majority of studies showing a benefi cial effect. 3 One article identifi ed, in a small population of pediatric patients, that patients who received PN without supplemented carnitine had low serum carnitine levels. 7 At Primary Children's Hospital, the amount of carnitine supplementation in PN increased more than 9-fold in 2012. This was in response to testing of carnitine levels in the neonate and infant population. In this study, we evaluated serum carnitine levels in patients to determine whether there was a weight range-specifi c defi ciency and a statistical association for carnitine-supplemented patients versus nonsupplemented patients. We assessed carnitine serum levels to determine whether there is a weight range at which carnitine should automatically be supplemented in PN without needing to draw a carnitine level. Additionally, we wanted to determine whether decreased glucose and elevated triglyceride levels are associated with a carnitine defi ciency.
METHODS
This was a retrospective observational study approved by the institutional review board to evaluate 2 groups of pediatric patients (from 0.68 kg to 60 kg) who were NPO and receiving PN. The fi rst group of patients (n = 454) received carnitine supplementation (15 mg/kg/day) upon initiation of PN. The second group (n = 299) did not receive carnitine supplementation until it was determined that they had a carnitine defi ciency by a carnitine serum assessment. Standard laboratory carnitine values were assessed using total carnitine, free carnitine, esterifi ed carnitine, and the ratio of esterifi ed to free ( Table 1) . Carnitine defi ciency was determined by low free carnitine levels or an esterifi ed to free carnitine ratio greater than 0.4. Patients were assessed by weight ranges: 0 to 2.5 kg, 2.51 to 5 kg, 5.01 to 7.5 kg, 7.51 to 10 kg, and greater than 10 and less than 60 kg. Weight ranges were assessed to determine which weights had low levels of free carnitine requiring supplementation. Patients were excluded if they had cardiopulmonary bypass, extracorporeal membrane oxygenation (ECMO), renal dialysis, or spinal muscular atrophy (SMA). The free carnitine levels indicated that supplemented and nonsupplemented patients in the 0 to 5 kg and greater than 5 kg weight ranges could be compared by calculating the percentage of patients that were low, within normal limits (WNL), and high levels. A statistical review of supplemented and nonsupplemented carnitine-free levels was assessed using a Mann-Whitney nonparametric statistical test to determine whether there was a statistical difference in the supplemented versus nonsupplemented patients.
Triglyceride and blood glucose levels were evaluated in the nonsupplemented patients before and after carnitine supplementation if needed. Patients supplemented with carnitine initially had their triglyceride and blood glucose levels evaluated at the initiation of PN and 30 days later. A Mann-Whitney test was used to statistically evaluate the triglyceride and blood glucose levels in nonsupplemented and supplemented patients before and after PN.
RESULTS
Carnitine-supplemented patients (n = 454) received a dose of 15 mg/kg/day and averaged 30 days of supplementation before levels were obtained.
In all weight ranges, the average total carnitine level, esterifi ed carnitine level, and free carnitine level were found to be within the normal level range. The esterifi ed to free carnitine ratio for the 0 to 2.5 kg and the greater than 10 kg patients were within the normal range of 0.25 to 0.4. However, the esterifi ed to free carnitine ratio was high (average, 0.54) for the 2.51 to 5 kg, 5.01 to 7.5 kg, and 7.51 to 10 kg groups. The percentage of carnitine levels that were low, high, and within normal range can be seen in Figure 1 .
In the nonsupplemented patients (n = 299), the number of days before a carnitine level was obtained averaged 13 days. Patients who had a low serum carnitine-free level were then dosed at 15 mg/kg/day. The average serum carnitine-free level for patients weighing 0 to 2.5 kg and 2.51 to 5 kg was low (17.64; range, 29-61) indicating a carnitine defi ciency and thus requiring supplementation. The average serum carnitine-free levels for patients weighing 5.01 kg to 60 kg were within normal limits. The average levels for the total and esterifi ed were abnormal for patients weighing 0 to 5 kg but were within normal limits for patients weighing more than 5.01 kg. The percentage of carnitine levels that were low, high, and within normal range can be seen in serum carnitine levels for the nonsupplemented and the supplemented patients, we found a difference (P = .001) (Figure 2) . A subset of 109 nonsupplemented patients was used to compare triglyceride and blood glucose levels before and after carnitine supplementation. The difference in the triglyceride levels before and after supplementation was not signifi cant (P = .6965). Comparison of glucose levels before and after supplementation showed a lower glucose level after carnitine supplementation (P = .0414). We expected that low glucose levels with a carnitine defi ciency refl ected increased utilization of glucose due to decreased ability to utilize fat for energy, but our results did not support this. Using a ratio of the triglyceride level before and after supplementation and comparing the same ratio for the glucose level before and after supplementation showed no difference (P = .118).
In a subset of 54 carnitine-supplemented patients, the triglyceride and blood glucose levels were drawn at the initiation of carnitine supplementation and 30 days after supplementation. Comparing the triglyceride and blood glucose levels at the initiation of carnitine supplementation and 30 days after supplemen-tation were not signifi cant (P = .2983 and P = .131, respectively). Using a ratio of the triglyceride level before and after supplementation and comparing the same ratio for the glucose level before and after supplementation showed no difference (P = .1936).
DISCUSSION
This retrospective study was conducted because most research has been focused on patients weighing less than 2 kg. We found that patients need carnitine supplementation at a higher weight. The majority of our patients weighing less than 5 kg required supplementation based on serum carnitine levels. Even in patients with higher weights, there were a certain percentage of patients who had low carnitine levels without supplementation. The literature indicates that most pediatric patients on carnitine-free PN have low carnitine levels within 7 to 10 days without carnitine supplementation. These data from the literature prompted the implementation of a protocol at our institution to check serum carnitine in patients with carnitine-free PN at 7 days. Based on this carnitine level, carnitine was either started or not added to the patient's PN. Due to our results, we have changed the practice at our institution. Patients who weigh less than 5 kg and are on PN are supplemented with carnitine at 15 mg/kg/day. A carnitine level is checked at 4 days of PN to determine whether carnitine supplementation needs to be continued, discontinued, or the dose adjusted. For patients weighing more than 5 kg who are going to be on PN for longer than 7 days or are medically compromised, carnitine levels are drawn after 7 days. If the patient's carnitine level is low, thus indicating a defi ciency, carnitine is added to the PN at 15 mg/kg/day. Carnitine levels are monitored monthly thereafter.
The fi ndings from our study changed our hospital's monitoring and ordering of carnitine. We updated our computerized physician order entry system for PN. We added hard stops on ordering carnitine and provided education windows explaining the new policy for ordering carnitine in PN.
Before this study, we often assumed an association between glucose and triglyceride levels and carnitine stores in our patients. Our hypothesis was that high triglyceride and low glucose levels were associated with low carnitine levels. Our data indicate that there is no statistical association between triglyceride, glucose, and carnitine levels; this is in agreement with the study by Dahlstrom et al. 7 Carnitine levels (free, esterifi ed, and total) should be monitored to assess for carnitine defi ciency.
CONCLUSION:
After reviewing the retrospective data from our institution, we suggest that patients weighing less than 5 kg should be supplemented with carnitine.
A serum carnitine level should be drawn within 4 days of supplementation to assess whether dose adjustment should be made. Patients who are not supplemented with carnitine should have serum levels drawn within 7 days to determine whether they require supplementation. Carnitine supplementation should be based on serum levels.
